References
- 1. Liu J, Wang D, Li H, et al - Clinical value of contrast-enhanced ultrasound in diagnosis of hyperechoic liver lesions. Med Sci Monit. 2015; 21:2845
- 2. Casali PG, Blay JY - ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21:98-102
- 3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR - Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016; 40:39-46
- 4. Wozniak A, Rutkowski P, Piskorz A, et al - Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol. 2011; 23:353-360
- 5. Ducimetière F, Lurkin A, Ranchere-Vince D, et al - Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PloS one. 2011; 6: e20294.
- 6. Hechtman JF, DeMatteo R, Nafa K, et al - Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): a clinicopathologic study of 260 patients with molecular analysis and review of the literature. Ann Surg Oncol. 2015; 22:2633-39.
- 7. D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP - Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015; 205: W56-W66
- 8. Hohmann J, Muller A, Skrok J, et al - Detection of hepatocellular carcinoma and liver metastases with BR14: a multicenter phase IIA study. Ultrasound Med Biol. 2012; 37: 377-382.
- 9. Claudon M, Dietrich CF, Choi BI, et al - Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013; 39: 187-210.
- 10. Nishida T - The Role of Endoscopy in the Diagnosis of Gastric Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2015; 22: 2810-2811.
- 11. Watson RR, Binmoeller KF, Hamerski CM, et al - Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors. Dig Dis Sci. 2011; 56: 1757-1762.
- 12. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M - CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11: 728-734
- 13. West RB, Corless CL, Chen X, et al - The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors, irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004; 165: 107-13.
- 14. Shi YN, LI Y, Wang LP, et al - Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine. 2017; 96: e8240.
- 15. Abuzakhm SM, Acre-Lara CE, Zhao W, et al. Unusual metastases of gastrointestinal stromal tumor and genotypic correlates: Case report and review of the literature. J Gastrointest Oncol. 2011, 2.1: 45
- 16. Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology, 2003; 226.2: 527-532.
- 17. Blanke CD, Demetri GD, von Mehren M, et al - Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26: 620–25.
- 18. Blanke CD, Rankin C, Demetri GD, et. al - Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26: 626–32.